Patents by Inventor Adeniyi ADEBESIN

Adeniyi ADEBESIN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • KIDNEY-TARGETED EPOXYEICOSATRIENOIC ACID (EET) ANALOGS
    Publication number: 20220251100
    Abstract: Described here are EET analogs conjugated to folate receptor ligands such as folic acid or folic acid analogs recognized by and selectively bound by folate receptors and other folate binding proteins and the use of such conjugated EET analogs for targeted delivery of therapeutic agents to folate-receptor bearing cell populations. More particularly, provided herein are EET analogs conjugated to folate receptor ligands and uses of such conjugated EET analogs as kidney targeted therapeutics.
    Type: Application
    Filed: April 26, 2022
    Publication date: August 11, 2022
    Inventors: John D. Imig, John R. Falck, Abdul Hye Khan, Adeniyi Adebesin
  • Substituted epoxyeicosatrienoic acid (EET) analogs for treatment of kidney disease
    Patent number: 11358968
    Abstract: Described here are EET analogs conjugated to folate receptor ligands such as folic acid or folic acid analogs recognized by and selectively bound by folate receptors and other folate binding proteins and the use of such conjugated EET analogs for targeted delivery of therapeutic agents to folate-receptor bearing cell populations. More particularly, provided herein are EET analogs conjugated to folate receptor ligands and uses of such conjugated EET analogs as kidney targeted therapeutics.
    Type: Grant
    Filed: September 14, 2018
    Date of Patent: June 14, 2022
    Assignee: The Medical College of Wisconsin, Inc.
    Inventors: John D. Imig, John R. Falck, Abdul Hye Khan, Adeniyi Adebesin
  • KIDNEY-TARGETED EPOXYEICOSATRIENOIC ACID (EET) ANALOGS
    Publication number: 20200255433
    Abstract: Described here are EET analogs conjugated to folate receptor ligands such as folic acid or folic acid analogs recognized by and selectively bound by folate receptors and other folate binding proteins and the use of such conjugated EET analogs for targeted delivery of therapeutic agents to folate-receptor bearing cell populations. More particularly, provided herein are EET analogs conjugated to folate receptor ligands and uses of such conjugated EET analogs as kidney targeted therapeutics.
    Type: Application
    Filed: September 14, 2018
    Publication date: August 13, 2020
    Applicant: THE MEDICAL COLLEGE OF WISCONSIN, INC.
    Inventors: John D. Imig, John R. Falck, Abdul Hye Khan, Adeniyi ADEBESIN